AGILENT TECHNOLOGIES, INC. (A) SEC Filings

Agilent Technologies, Inc. is offering to exchange up to $600,000,000 aggregate principal amount of registered 4.900% Senior Notes due 2032 for any and all outstanding unregistered notes of the same series. It will issue $1,000 principal amount of Exchange Notes for each $1,000 principal amount of Original Notes validly tendered and not withdrawn; exchanged Original Notes will be retired and canceled.

The offer expires at 5:00 p.m. New York City time on September 30, 2026, unless extended or earlier terminated; holders may withdraw tenders through the expiration. Agilent will receive no cash proceeds. Interest accrues at 4.900% per annum, payable semiannually on January 15 and July 15, beginning January 15, 2027.

The notes are senior unsecured obligations ranking equally with Agilent’s unsecured and unsubordinated debt, effectively junior to secured debt and structurally junior to subsidiary liabilities. As of July 31, 2026, Agilent had approximately $3.9 billion of total outstanding debt, inclusive of the Original Notes; its subsidiaries had approximately $1,212 million of liabilities, excluding intercompany liabilities and deferred revenue. The Exchange Notes will not be listed on a national securities exchange, and Agilent cannot assure that a public market for them will develop.

AGILENT TECHNOLOGIES, INC. (symbol: A) is the issuer of record for a Form 4 filing submitted to the SEC. Boehnlein Glenn S reported acquisition or exercise transactions in this Form 4 filing.

AGILENT TECHNOLOGIES, INC. (A) reported that director Glenn S. Boehnlein received an award of 817 shares of common stock on September 8, 2026, described as common stock for Non-Employee Directors that is fully vested upon grant at a reference value of $146.85 per share. Following this grant, Boehnlein holds 817 shares directly, and an additional 35 shares are held indirectly through the Boehnlein 2017 Trust, for which Glenn and Susan Boehnlein serve as trustees. No transactions were reported under a Rule 10b5-1 trading plan.

AGILENT TECHNOLOGIES, INC. (A) reported the initial ownership statement of director Glenn S. Boehnlein. The filing shows he holds no shares of common stock directly and holds 35 shares of common stock indirectly through the Boehnlein 2017 Trust, for which Glenn and Susan Boehnlein serve as trustees.

AGILENT TECHNOLOGIES, INC. (A) director Mikael Dolsten reported selling 634 shares of common stock on September 4, 2026, in an open-market or private transaction at $151.375 per share. After this sale, he held 4,923.680 shares directly, including 9.295 shares acquired through a dividend reinvestment plan and deferred. No Rule 10b5-1 trading plan is reported for this transaction.

Agilent Technologies, Inc. (A) reported governance changes to its board of directors. On September 2, 2026, longtime director and board chair Boon Hwee Koh notified the company of his decision to retire from the board, effective September 4, 2026, after roughly 23 years of service; the company states his decision was not due to any disagreement regarding operations, policies, or practices.

Effective September 4, 2026, the board appointed Glenn Boehnlein, age 64 and former Vice President and Chief Financial Officer of Stryker Corporation, as a Class III director, and named him to the Audit and Finance Committee and the Compensation Committee. The board determined that he is independent under New York Stock Exchange corporate governance standards and that he qualifies as an “audit committee financial expert.” Separately, the board elected Dow R. Wilson, a director since 2018, to serve as board chair.

Agilent describes Boehnlein’s background in senior finance roles at Stryker, prior CFO and audit experience, and current board roles at Inogen Inc. and Sutter Health. He will receive the company’s standard non-employee director compensation and enter into Agilent’s standard indemnification agreement. Agilent also notes that it generated $6.95 billion in revenue in fiscal 2025 and employs about 18,000 people worldwide.

AGILENT TECHNOLOGIES, INC. (A) reports that director Mikael Dolsten has filed a notice to sell 634 shares of the company’s common stock, with an aggregate market value of $95,971.75, through Fidelity Brokerage Services LLC on the NYSE on September 4, 2026.

The shares derive from restricted stock vesting on March 19, 2026 that was issued as compensation by the company.

Agilent Technologies, Inc. (A) is conducting an Exchange Offer to swap up to $600,000,000 aggregate principal amount of its outstanding unregistered 4.900% Senior Notes due 2032 for substantially identical notes registered under the Securities Act. No cash changes hands; original notes tendered will be retired and canceled.

The Exchange Notes are general senior unsecured, unsubordinated obligations ranking pari passu with all of Agilent’s other senior unsecured debt and effectively junior to any future secured debt. They are structurally subordinated to liabilities of subsidiaries, which totaled $1,212 million as of July 31, 2026. Total senior unsecured debt was about $3.9 billion.

The notes pay 4.900% interest, payable semi-annually each January 15 and July 15, starting January 15, 2027, and mature in 2032. Agilent may redeem them before December 15, 2031 at a make-whole price based on a Treasury Rate, and at par plus interest thereafter. A change of control repurchase event triggers an obligation to offer to repurchase at 101% of principal plus accrued interest. The Exchange Offer expires at 5:00 p.m., New York City time, on September 30, 2026, unless extended, and non-tendered Original Notes will remain restricted and may be less liquid. The Exchange Notes will not be listed on any securities exchange.

Agilent Technologies, Inc. (A) has filed an automatic shelf registration statement on Form S-3 as a well‑known seasoned issuer, allowing it to issue debt securities, including convertible debt, in one or more series from time to time. No limit exists on the aggregate principal amount of debt securities that may be sold under this registration.

The debt may be denominated and payable in U.S. dollars or foreign currencies, issued in minimum denominations of $1,000, and governed by an existing indenture with Citibank, N.A. as trustee. Covenants include limitations on liens, sale‑leaseback transactions, and certain consolidations, mergers and sales of assets, with cross‑default triggers tied to indebtedness over $100 million.

Net proceeds are expected to be used for general corporate purposes, which may include share repurchases, working capital, capital expenditures, debt repayment, and financing acquisitions and investments. Agilent may sell these securities through underwriters, dealers, agents, or directly, and the securities may or may not be listed on a securities exchange.

Agilent Technologies, Inc. (A) reported higher sales and earnings for the three and nine months ended July 31, 2026, while executing a sizeable acquisition and adding new debt. Quarterly net revenue was $1.878 billion, up from $1.738 billion a year earlier, and net income was $362 million versus $336 million. Diluted EPS rose to $1.28 from $1.18 as operating income improved to $444 million, reflecting stronger product and service revenues across regions and end markets.

For the first nine months, revenue grew to $5.511 billion from $5.087 billion and net income to $1.006 billion from $869 million, supported by solid operating cash flow of $1.064 billion. Agilent closed the $950 million acquisition of Biocare, expanding its pathology offering, and issued $600 million of 2032 senior notes, increasing long-term debt to $3.645 billion while ending the period with $1.758 billion of cash. The company continued share repurchases and paid $0.765 per share in dividends year-to-date, and is incurring restructuring charges to streamline its organization. Management also notes uncertainty around potential tariff refunds and geopolitical tensions, though these had no material impact through the third quarter.